” We harness cutting-edge AI technology for data processing, modeling, and personalized risk stratification in clinical decision support. “
We’re excited to share our latest company news with you. If you’re interested in partnering with us, just drop us an email — we’re always here to help.
Our deep learning service focuses on developing personalized treatment plans for liver cancer patients by integrating imaging, pathology, and genomic data, providing comprehensive disease assessment and precise treatment recommendations. Our system leverages advanced deep learning models to automate the analysis of liver images, while also incorporating genomic data to offer doctors tailored recommendations for targeted therapies, treatment efficacy predictions, and prognostic assessments. Additionally, we provide a similar patient search feature, enabling physicians to access comparative pathology data to aid in treatment planning.
Our solution not only enhances the accuracy of early liver cancer detection but also enables real-time monitoring of treatment responses, ensuring the most appropriate therapeutic approach for each patient. Moreover, our service is currently undergoing multi-center clinical validation to ensure its feasibility and safety in clinical practice.
Cancer, especially liver cancer, remains a major health issue. Despite advances in treatment and drug development, many patients still don’t achieve ideal results. The reasons are unclear, often due to tumor complexity, genetic differences, and unpredictable treatment responses. Our deep learning solution helps bridge this gap by providing personalized treatment plans using imaging, pathology, and genomic data.
Virtual patient simulation could help determine which treatment option would provide the optimal benefit to a patient before treatment.
AI-encoded biomarkers accompanied by the simulation, so-called Deep features, individually characterize the clinical outcome prediction in an “omics-like” profile.
Using a QR code, Deep Features of a patient before treatment can be exchanged between healthcare units to search for the real-world data of similar cases with known clinical outcomes.
Overall, we sell Virtual Patient Simulation Systems, Personalized Deep Features, and Real-World Data Search Systems to healthcare sectors, insurance companies, patients, and the public. As over 19 million new cancer cases are reported globally each year, we anticipate the gross margin will approach 90% and profits $107M in 4 years.
” We harness cutting-edge AI technology for data processing, modeling, and personalized risk stratification in clinical decision support. “
